To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
25 Current news about the topic anti-inflammatory drugs
rss
Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema
27-02-2008
Welichem Biotech Inc. announced that Health Canada approved the Company's Clinical Trial Application (CTA) to begin a Phase IIa Clinical Trial of its anti-inflammatory drug candidate, WBI-1001, on atopic dermatitis (a type of eczema). The Company will initiate its Phase IIa Clinical Trial of ...
Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis
26-11-2007
Chi-Med, the Hutchison Whampoa backed pharmaceutical and healthcare Group, announced that it's wholly-owned drug R&D subsidiary, Hutchison MediPharma Limited, has obtained clearance for its new Investigative New Drug ("IND") application from the US Food and Drug Administration for its drug ...
BioXell Initiates Phase IIa Trial of its Lead Compound BXL628 in Chronic Non-Bacterial Prostatitis
09-11-2005
BioXell SpA announced the initiation of a Phase IIa trial to investigate the efficacy of its lead compound BXL628, a non-hypercalcemic Vitamin D Receptor (VDR) agonist, in chronic non-bacterial prostatitis (CP/CPPS). Coordinated by the Division of Urology at the University "La Sapienza" in ...
Genzyme Completes Purchase of Synvisc Sales and Marketing Rights
07-01-2005
Genzyme Corp. announced that it has completed the transaction to buy back the sales and marketing rights to Synvisc® (hylan G-F 20) in the United States and five European countries from Wyeth. The cash transaction is accretive to Genzyme. Genzyme will now record all Synvisc end-user revenue ...
Go ahead for A-Virals first human study in Europe
Therapy of inflammatory diseases, autoimmune diseases or tissue rejection
26-11-2003
A-Virals first human study in Europe is approved by the Ethics Committee at The Academical Medical Centre, Amsterdam. The study will be carried out under the supervision of Professor Dr. Med. Tom van der Poll at AMC, which is one of Amsterdam's larger hospitals, and also one of the city's ...
Netmeeting
